Pfizer Inc. shares moved lower in after-hours trading after the company disclosed that its Phase 3 SigVie-002 trial missed its primary endpoint. The stock fell 1.5% to $24.70 following confirmation that sigvotatug vedotin failed to produce a statistically significant improvement in overall survival compared with docetaxel in a study of 703 patients with previously treated locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer.
The result represents a material blow to Pfizer’s oncology ambitions. Management and investors have highlighted the oncology pipeline as a key element of the company’s growth strategy since the pandemic, and the Phase 3 disappointment removes a potential contributor to future revenue and growth expectations.
Compounding the clinical setback, Pfizer is also managing a leadership change in its finance team. Chief Financial Officer Dave Denton announced he will step down on August 15 to pursue an opportunity in the consumer goods sector. The company named Cecile Guegan, a finance executive with more than two decades at Pfizer, as interim CFO effective August 16 while a permanent successor is sought.
Analysts have taken note. Goldman Sachs analyst Asad Haider reiterated a Hold rating and maintained a $26 price target, pointing to the CFO transition and uncertainty around clinical upside. The trial outcome directly relates to the clinical uncertainty Haider highlighted.
Markets provided limited support for Pfizer’s shares on the day. The S&P 500 slipped 0.4% and the Nasdaq Composite declined 1.3%, with notable weakness in large technology names including Alphabet and Amazon, while the Dow Jones Industrial Average rose 0.3%, helped by gains in Caterpillar. Investors were adopting a cautious posture ahead of impending inflation data, a focus for the Federal Reserve after signals at the June FOMC meeting that a rate hike later in 2026 remains possible.
Taken together, the Phase 3 miss, the unresolved CFO succession and a generally risk-off tone in equities have driven Pfizer toward the lower end of its recent trading range. The stock remains well below its 52-week high of $28.75. With the company’s next earnings release not scheduled until August 4, market participants appear to be waiting for further clarity on whether Pfizer’s pipeline can generate the growth necessary to offset pressures from patent expirations and other headwinds.
Summary
Pfizer shares fell in after-hours trade after its Phase 3 SigVie-002 study of sigvotatug vedotin failed to demonstrate a statistically significant overall survival benefit versus docetaxel in 703 patients with previously treated non-squamous non-small cell lung cancer. The clinical disappointment arrives amid a planned CFO departure, with an interim CFO to take the role while a permanent replacement is sought. Broader market weakness and investor caution ahead of inflation data added pressure. The stock sits well below its 52-week high, and the next earnings report is scheduled for August 4.